Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year
Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.
You may also be interested in...
The drug maker is pointing to potential biweekly dosing as raising the possibility for the bispecific’s use in community oncology, though an expert had said it could take some time for that to happen.
Phase II studies of vaccines involve more variables than for drugs and these can be compounded by seasonality. This can make the time until vaccine approval longer than would be expected for drugs.
Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.